chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This case was reported by a physician via sales rep and described the occurrence of weakness in a 56-year-old male patient who received SHINGRIX for prophylaxis. The patient's past medical history included dyslipidemia and overweight. On an unknown date, the patient received the 1st dose of SHINGRIX. On 16th June 2018, less than a year after receiving SHINGRIX, the patient experienced weakness (serious criteria hospitalization), palpitation (serious criteria hospitalization) and chest discomfort (serious criteria hospitalization). On an unknown date, the outcome of the weakness, palpitation and chest discomfort were unknown. It was unknown if the reporter considered the weakness, palpitation and chest discomfort to be related to SHINGRIX. Additional information was received as follows: The age at vaccination was not reported. However, it could be 55 or 56 years old. The patient received SHINGRIX vaccine at an unknown pharmacy. The reporter was notified that the patient had weakness, palpitations and intermediate chest discomfort after receiving SHINGRIX. The patient went to emergency room and was admitted.
pt recv vax & subsequently pt devel GBS;@ the time of the report, no further info was available;
This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (numbness of the face and neck) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced HYPOAESTHESIA (numbness of the face and neck). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency and IBUPROFEN at an unspecified dose and frequency. At the time of the report, HYPOAESTHESIA (numbness of the face and neck) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.
Suddenly had hair loss so severe I had to get a wig. I went to the doctor and mentioned that I'm aware that as people get older, they lose their hair. One day I had hair and the next day I had no hair. My hair has not grown back yet. It will take 6 months to a year for my hair to grow back.
I  experienced numbness and swelling in my legs and feet. My health is slowly deteriorating. I became lethargic and highly fatigued which I believe is due to the fact that my kidneys are failing, Test were completed on my lower legs to check my circulation. The checked my lungs and said there were nodules in my lungs. The did an MRI and bowel exam due to my bowel getting very watery similar to irritable bowl movement type symptoms. I was in excellent health for the majority of my life. I have been prescribed medication for my blood pressure and for my bowels. I have changed my diet completely and increased my exercise to help improve.
Employee had a seizure and LOC approx. 2 hrs post second vaccine.  EMS was called and employee was transported to the hospital.  Employee was hospitalized for observation.  Discharged home after 2 days.  Employee still reports feeling weak.  Following up with primary care MD.
shingles; broke out in a rash; =This is a spontaneous report from a contactable consumer (patient). This 64-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 17Mar2021 at single dose for COVID-19 immunization.  The patient age at vaccination was 64-year-old. Medical history was none. The patient's concomitant medications were not reported.  The patient was due to take her second Pfizer covid vaccine on Wednesday.  Her first was 17Mar2021. Last Sunday, 28Mar2021, she broke out in a rash.  She had a telehealth appointment with her doctor who gave her cephalexin and said if it didn't resolve in 7-10 days, to let her know.  Patient stated it has gotten worse and she thought it was shingles. She had an appointment with her doctor Wednesday morning at 7:45 and was supposed to get her second covid vaccine at 1:15. Doctor said she thought it would be okay to get it. Therapeutic measures were taken as a result of broke out in a rash. The outcome of the event broke out in a rash was not recovered, of other event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Severely painful joints and muscles, mental fog, headache, nausea, chills, fatigue.
The caller's doctor has a man who had the same exact symptoms as the caller and it lasted 2 weeks after the vaccine/nausea; This is a spontaneous report from a contactable consumer or other non hcp. This Consumer reported for a male patient that. A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date at dose number unknown, single for covid-19 immunisation. Medical history and concomitant medications were not reported. On an unspecified date the patient experienced the caller's doctor has a man who had the same exact symptoms as the caller and it lasted 2 weeks after the vaccine/nausea. Outcome of the event was unknown.   Information on lot/batch number has been requested.  Follow-up (03Sep2021): No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient developed some chest pain heaviness in her left chest area. The pain was worse with a deep breath She took 6 baby aspirins prior to coming to the ER - did not help with the pain She rec'd Nitroglycerin SL and Tylenol 650mg. Cardiac enzymes were negative X 2. D-dimer was negative.  Patient was discharged without any further incidents
Within 60 seconds, post vax, the injection site became to redden to 4cm X 5cm with a 4.5cm area of induration. He was given 3/4 tsp of Benadryl and observed in the office for 2 hours. The area faded significantly. Within 1 hour after discharge, he returned with red blotching to his extremities and puffy eyelids, no respiratory distress, stridor or wheezing or edema. He was prescribed Prelone x 3 days and told to double his dose of Zyrtec X 3 days. Follow-up the next day the extremity had faded significantly. His allergist was notified, so his MMR will be given at his office.
Maculo-papular vesicular rash on back 5-6, few had scabbed, 1-2 on the arms.
patient had a seizure and lost consciousness; pt regained consciousness after a couple minutes; pale and perspiring, paramedics came and provided care from there
Left arm with 6cm by 8 cm area of erythema without fluctuance noted. Area is tender and warm to touch, location of vaccine is 2cm above area of redness. No lymphadenopathy noted. Dx: cellulitis tx = BACTRIM DS 1 tab BID x 10d.
This spontaneous report as received from a Medical Assistant refers to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On an unknown date in July 2008, the patient was vaccinated with the first dose of GARDASIL, then a second dose was administered on an unspecified date in July 2011 and the third dose on 30-JUN-2015 (administration routes, lot numbers and expiration dates were not provided). No concomitant therapies were reported. No adverse events were reported. Additional information has been requested.
Information has been received from a nurse concerning her 22 year old daughter with no medical history, who on 20-MAR-2007 was vaccinated intramuscularly (arm unspecified) with a dose of Gardasil. No concomitant medications. Subsequently, the patient developed a light raised scar at the injection site. It was reported that the area looks like scar tissue. It was mentioned that her daughter has dark skin and the scar appears white or lighter than her skin. Additional information is not expected.
Approximately about 2 months after my 2nd dose I experienced the following symptoms: Ringing in both ears. I consulted with my doctor regarding this and was advised to see an Ear specialist. When I saw the ear specialist, she did a hearing test and it was normal. She also sent me to do blood work and MRI which are both scheduled next week.
On 12/11/00 the patient received Hep B vaccine in the left thigh, pneumo given in the right thigh. The patient developed a fever of 104 that evening, short generalized seizure. The patient was seen in the ER, the exam was unremarkable except for a fever.  The chest x-ray, CBC, and U/A were wnl. The patient had swelling and erythema in the right thigh at the injection site. The patient was discharge home and saw MD 12/13/2000. The mother states the patient still had a fever. Although afebrile the exam was normal, except for a 3cm induration area with some erythema on the right thigh.
Got the first 2 doses 22 days apart; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Got the first 2 doses 22 days apart) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 26-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Got the first 2 doses 22 days apart). On 16-Jun-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Got the first 2 doses 22 days apart) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant mediations were reported.  No treatment medications were reported.
itching at rash sites; Sore arm; pain at injection site; Injection site redness; Injection site rash/ Rash on arm/ rash spread down to just above the elbow/worsening rash; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 78-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles.   On 14th August 2019, the patient received the 1st dose of Shingrix (intramuscular). On 14th August 2019, less than a day after receiving Shingrix, the patient experienced injection site pain, injection site erythema and injection site rash. On 15th August 2019, the patient experienced pain in arm. On 21st August 2019, the patient experienced itchy rash. On an unknown date, the outcome of the injection site pain, injection site erythema, injection site rash, pain in arm and itchy rash were unknown.   It was unknown if the reporter considered the injection site pain, injection site erythema, injection site rash, pain in arm and itchy rash to be related to Shingrix.  Additional case details were provided as follows: The patient received Shingrix in the right arm. The patient had injection site pain.  She also reported redness and rash at injection site which began on the day of vaccination.  The next day, her arm was sore.  One week after the injection, the rash remained and had become itchy.  The patient also stated that, the rash had now spread down to just above the elbow.  The patient did not consent to follow up.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 24-SEP-2013, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided) at a pharmacy, as recommended for routine adult health maintenance for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. On or about 13-NOV-2015, the patient was treated for a blistering vesicular outbreak that was diagnosed as severe herpes zoster. The patient was prescribed gabapentin and valacyclovir for management of her painful symptoms and chronic pain. The outcome of the events is unknown. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for the long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
PATIENT SAID IT FELT LIKE HER THROAT WAS CLOSING UP AND SHE WAS HAVING DIFFIBULTY BREATHING.  IT BEGAN ABOUT 15-20 MINUTES AFTER RECEIVING HER SECOND COVID VACCINE.   SHE DESCRIBED HER THROAT BURNING AND NOT BEING ABLE TO CATCH HER BREATH.
Patient was transfered to our facility after developing severe headache, meningitis in setting of zoster of left upper arm (site of previous vaccination 7 years prior).   CSF had pleocytosis and was PCR + for VZV at outside facility, negative at our facility after 3 days of acyclovir intervenously.   Isolate subsequently identified as vaccine-strain from both arm lesions and CSF. 6/26/08-recoreds received for DOS 6/14-6/20/07-DC DX: VZV meningitis. Presented with headache and photophobia. 9 days PTA itchy lesion on left shoulder which spread into vesicular rash over next 2 days. 6 days PTA diagnosed with shingles. 5 day PTA developed severe headache, neck stiffness, photophobia vomiting, sleepy.
Febrile seizure, temp 104.3(temporal). Skin rash on trunk. 11/17/09 ER records received for date 8/26/09 to 8/27/09.  DX: febrile seizure vaccine related varicella. Presented to ER via EMS: crying, irritable, tachycardia. Assessment: rash, fever, seizure, vesicles on tonsils. Upon dc sx. resolved.
2-22-02 Day following vaccine, started with approximately smaller hives turning into larger 8-12 diameter. Itching noted. Covered tops of legs and went over body. Denies SOB or N & V post immunizations. Interpreter to help. Denies going to ER. Also denies any  difference in foods, bathing soaps or activities of daily living.
Patient stated he might of passed out for a few seconds. He also stated he felt dizzy and nauseated . Onsite EMS was called vitals HR 56 BP 105/68. Patient was released to go home.
This spontaneous case was reported by a nurse and describes the occurrence of IMMUNISATION REACTION (mild side effects after her second dose of the Moderna Covid-19 vaccine) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Concurrent medical conditions included Postural orthostatic tachycardia syndrome (evolved from Dysautonomia in the Summer of 2021.) since 2021, Epstein-Barr virus infection (happened years before she received her Moderna Covid-19 vaccine) and Dysautonomia. Concomitant products included PARACETAMOL (ACETAMINOPHEN) for an unknown indication. In 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced IMMUNISATION REACTION (mild side effects after her second dose of the Moderna Covid-19 vaccine). At the time of the report, IMMUNISATION REACTION (mild side effects after her second dose of the Moderna Covid-19 vaccine) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: results not reported Results not reported. On an unknown date, Computerized tomogram: results not reported Results not reported. On an unknown date, Magnetic resonance imaging heart: results not reported Results not reported. On an unknown date, Tilt table test: results not reported Results not reported.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The concomitant medications were reported as Beta Blocker and Anti Inflammatory.   Patient had a symptoms like fainting spells, tachycardia, GI symptoms, nausea, diarrhea, feeling of burning in her body in May 2000 . The patient went to long Covid-19 vaccine clinic in the summer of 2021.The symptoms were diagnosed as autonomic nerve system damage/ due to Epstein Barre Syndrome. and then into the Dysautonomia and Potts Syndrome.    Patient received second dose of the Moderna Covid-19 vaccine in May or June of 2021 and was not sure about the lot number, expiration date and also the arm where vaccination was administered.  No treatment medication was reported.   This case was linked to MOD-2022-580233, MOD-2022-580214 (Patient Link).
Fever (103.2 degrees); chills; muscle aches; fatigue; headache; diarrhea; joint pain; first single dose of BNT162B2 on 23Dec2020 03:30 PM, second dose on 15Jan2021 16:15; This is a spontaneous report from a contactable physician (patient). A 32-year-old female patient receive second single dose of BNT162B2 (Solution for injection, lot number: EL3302, exp date not reported), via an unspecified route of administration (vaccine location: Left arm) on 15Jan2021 16:15 for Covid-19 immunization. Facility where the most recent COVID-19 vaccine was administered: Hospital. Medical history included Celiac disease, asthma, and allergies to latex and gluten. The patient was not pregnant at the time of vaccination and was not pregnant at the time of reporting. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medication/other medications received within 2 weeks of vaccination included fluoxetine hydrochloride (PROZAC) and ethinylestradiol, levonorgestrel (SEASONIQUE). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously took first single dose of BNT162B2 (lot number: EL1284) on 23Dec2020 03:30 PM on the left arm for Covid-19 immunization. On 16Jan2021 04:00, the patient experienced fever (103.2 degrees), chills, muscle aches, joint pain, fatigue, headache, and diarrhea. The events were considered as non-serious by the reporter. Treatment received for the adverse events included paracetamol (TYLENOL). Since the vaccination, the patient has not been tested for COVID-19. The patient recovered from fever (103.2 degrees), chills, muscle aches, joint pain, fatigue, headache, and diarrhea on an unspecified date in Jan2021.
Information has been received from a consumer from a medical office concerning a 75 year old male who on Oct 10, 2002 was vaccinated with a dose of pneumococcal vaccine 23 polyvalent (lot #642749/0111M). In Oct 2002, the patient developed injection site reaction. The patient sought unspecified medical attention. The reporter provided information regarding three other patients (WAES0210USA01938, 0210USA02077 and 0210USA02079). Additional information has been requested.
Received thawed vials on 13-OCT-2022 with a note that it expires on 13-OCT-2022 and administered vaccine on 16-Nov-2022; No adverse event; Patient received expired first primary dose beyond 30-day Use By Date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received expired first primary dose beyond 30-day Use By Date), PRODUCT STORAGE ERROR (Received thawed vials on 13-OCT-2022 with a note that it expires on 13-OCT-2022 and administered vaccine on 16-Nov-2022) and NO ADVERSE EVENT (No adverse event) in a child male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Nov-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received expired first primary dose beyond 30-day Use By Date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Received thawed vials on 13-OCT-2022 with a note that it expires on 13-OCT-2022 and administered vaccine on 16-Nov-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received expired first primary dose beyond 30-day Use By Date), PRODUCT STORAGE ERROR (Received thawed vials on 13-OCT-2022 with a note that it expires on 13-OCT-2022 and administered vaccine on 16-Nov-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Patient received expired first primary dose beyond 30-day Use By Date) and PRODUCT STORAGE ERROR (Received thawed vials on 13-OCT-2022 with a note that it expires on 13-OCT-2022 and administered vaccine on 16-Nov-2022).    No concomitant information was reported. The pediatric patient was of age 8-10 years. The unbroken carton vial size was 2.5ml. The vial did not underwent any temperature excursions. No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-673516 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-673516:same reporter
Patient called and expressed concern that her arm still hurt 2 and 1/2 weeks after receiving her flu shot and wanted to know what she should do. I ask specific questions about where it hurt and she said upper arm and included the shoulder area. She did not feel it was in the joint but it was just achy all the time and makes it difficult to sleep.
Hives on face, trunk and extremities. Since receiving vaccine eruptions occur roughly 3 times each week
received 1st dose approximately 1 year ago and would like to receive 2nd dose today 1/27/23.; no additional adverse events; This spontaneous report was received from a nurse concerning a 19-year-old female patient .  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date (reported as "approximately 1 year ago"), the patient was vaccinated with the firs dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 0.5 milliliter, administered as prophylaxis (strength, lot #, expiry date, and route of administration were not provided), and she wanted to received the second dose on 27-JAN-2023 (also reported as "today") (Inappropriate schedule of product administration). No additional adverse events were reported.
Extreme pain at injection site(right arm) Extreme pain at 1st dose injection site (left arm). Severe headache.  Stiff neck. Temperature 102.4. Severe chills. Rash on chest. Nausea. Cough. Chest tightness. Dizziness. Complete loss of appetite. Pain in both hands.
Chills, temp maximum of 100 degrees F and tingling sensation for approximately 48 hours after receiving Men B Vaccine.